Search research articles
Contact Us
Filters
Showing results (91-100 of 131) with videos related to
Page
of 14
Sort By:
Leukemia & Lymphoma
|
August 26, 2021
Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections
Maria Queralt Salas, Eshetu G Atenafu, Arjun Datt Law, et al.
International Journal of Cardiology
|
November 20, 2018
Retraction notice to "Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury" [Int. J. Cardiol. 163 (2013) 326-334]
Seán P Barry, Samir Ounzain, James McCormick, et al.
Annals of Hematology
|
February 23, 2023
Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experience
Eshrak Al-Shaibani, Shiyi Chen, Carol Chen, et al.
Transplantation and Cellular Therapy
|
May 9, 2021
Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation
Maria Queralt Salas, Eshetu G Atenafu, Arjun Datt Law, et al.
International Journal of Cardiology
|
October 28, 2011
Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury
Seán P Barry, Samir Ounzain, James McCormick, et al.
European Journal of Haematology
|
June 2, 2021
Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR
Igor Novitzky-Basso, Carol Chen, Shiyi Chen, et al.
Leukemia & Lymphoma
|
May 14, 2026
CMV reactivation post allogeneic stem cell transplantation decreases relapse risk and survival, and increases NRM - a single center analysis
Vered Stavi, Carol Chen, Igor Novitzky-Basso, et al.
JCO Oncology Practice
|
June 29, 2026
Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation
Nihar Desai, Sergio Rodriguez-Rodriguez, Carol Chen, et al.
Transplantation and Cellular Therapy
|
August 14, 2023
Choosing Between Older Matched Sibling Donor and Younger Matched Unrelated Donor in Allogeneic Hematopoietic Cell Transplantation: Comparison of Clinical Outcomes in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Mariana Pinto Pereira, Mats Remberger, Carol Chen, et al.
Transplantation and Cellular Therapy
|
April 22, 2024
Treosulfan- Versus Busulfan-based Conditioning in Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Single-center Retrospective Propensity Score-matched Cohort Study
Ivan Pasic, Tommy Alfaro Moya, Mats Remberger, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 131) with videos related to
Sort By:
Page
of 14
Leukemia & Lymphoma
|
August 26, 2021
Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections
Maria Queralt Salas, Eshetu G Atenafu, Arjun Datt Law, et al.
International Journal of Cardiology
|
November 20, 2018
Retraction notice to "Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury" [Int. J. Cardiol. 163 (2013) 326-334]
Seán P Barry, Samir Ounzain, James McCormick, et al.
Annals of Hematology
|
February 23, 2023
Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experience
Eshrak Al-Shaibani, Shiyi Chen, Carol Chen, et al.
Transplantation and Cellular Therapy
|
May 9, 2021
Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation
Maria Queralt Salas, Eshetu G Atenafu, Arjun Datt Law, et al.
International Journal of Cardiology
|
October 28, 2011
Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury
Seán P Barry, Samir Ounzain, James McCormick, et al.
European Journal of Haematology
|
June 2, 2021
Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR
Igor Novitzky-Basso, Carol Chen, Shiyi Chen, et al.
Leukemia & Lymphoma
|
May 14, 2026
CMV reactivation post allogeneic stem cell transplantation decreases relapse risk and survival, and increases NRM - a single center analysis
Vered Stavi, Carol Chen, Igor Novitzky-Basso, et al.
JCO Oncology Practice
|
June 29, 2026
Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation
Nihar Desai, Sergio Rodriguez-Rodriguez, Carol Chen, et al.
Transplantation and Cellular Therapy
|
August 14, 2023
Choosing Between Older Matched Sibling Donor and Younger Matched Unrelated Donor in Allogeneic Hematopoietic Cell Transplantation: Comparison of Clinical Outcomes in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Mariana Pinto Pereira, Mats Remberger, Carol Chen, et al.
Transplantation and Cellular Therapy
|
April 22, 2024
Treosulfan- Versus Busulfan-based Conditioning in Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Single-center Retrospective Propensity Score-matched Cohort Study
Ivan Pasic, Tommy Alfaro Moya, Mats Remberger, et al.
Page
of 14